We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19 TORONTO, Canada -- April 18, 2022 -- InvestorsHub NewsWire -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, Canada -- April 12, 2022 -- InvestorsHub NewsWire -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Expected to seek DSMB approval to proceed with EUA application to the FDA in...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to...
Β Revive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsΒ IRB approval to initiate Phase 2 study for methamphetamine abuse disordersΒ Advancing psilocybin oral thin film...
Β Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19Β Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment...
Β Β Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat CancerΒ Novel discovery and research originated from Universidad Central del...
Revive Confirms No Material Undisclosed Information Toronto, Ontario, Canada -- August 12, 2021 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd...
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution...
Β Revive Therapeutics Approved to Trade on the OTCQB MarketΒ TORONTO, June 25, 2021 -- InvestorsHub NewsWire --Β Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF, FRANKFURT:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.005 | 100 | 0.005 | 0.01 | 0.005 | 195545 | 0.00768501 | CS |
4 | -0.005 | -33.3333333333 | 0.015 | 0.015 | 0.005 | 424964 | 0.00959009 | CS |
12 | 0 | 0 | 0.01 | 0.015 | 0.005 | 303710 | 0.0088017 | CS |
26 | -0.01 | -50 | 0.02 | 0.025 | 0.005 | 472133 | 0.01150061 | CS |
52 | -0.025 | -71.4285714286 | 0.035 | 0.04 | 0.005 | 317387 | 0.01594792 | CS |
156 | -0.455 | -97.8494623656 | 0.465 | 0.49 | 0.005 | 340941 | 0.1385069 | CS |
260 | -0.025 | -71.4285714286 | 0.035 | 0.92 | 0.005 | 867497 | 0.30953958 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions